CRT-600.05 Eligibility for PCSK9 Inhibitor Treatment in 1090 Hypercholesterolemic Patients Referred to a Regional Cholesterol Treatment Center with LDL Cholesterol &gt;=70 mg/dl Despite Maximal Tolerated Cholesterol Lowering Therapy

descriptionPublicationkeyboard_double_arrow_right Article 01 Feb 2017 English Publisher:Elsevier BVJournal:JACC: Cardiovascular Interventions, volume 10, page S53 (issn: 1936-8798,

Copyright policy )

Authors: Kevin Lee; Sarah Min; Marloe Prince; Charles Glueck; Ping Wang; Kenneth Lee;

doi: 10.1016/j.jcin.2016.12.182

CRT-600.05 Eligibility for PCSK9 Inhibitor Treatment in 1090 Hypercholesterolemic Patients Referred to a Regional Cholesterol Treatment Center with LDL Cholesterol >=70 mg/dl Despite Maximal Tolerated Cholesterol Lowering Therapy

- Summary
- Metrics

Abstract

Lowering of LDL cholesterol (LDLC) has been revolutionized by PCSK9 inhibitors, Alirocumab (Praluent) and Evolocumab (Repatha). PCSK9 inhibitors have approved indications as adjunct to diet and maximally tolerated lipid lowering therapy (MTLLT) for patients with heterozygous familial

Related Organizations

Jewish Hospital
United States

Impact byBIP!

	selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	0
	popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.	Average
	influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	Average
	impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.	Average